The APRI score is a simple liver fibrosis score calculated from two common blood test results: AST and platelet count. It was developed to estimate the chance of significant scarring, or fibrosis, in the liver without immediately using a liver biopsy. APRI is most often discussed in chronic hepatitis C, chronic hepatitis B, and resource-limited settings, but it may also appear in broader liver disease evaluations. A high APRI score does not diagnose cirrhosis by itself. It means the blood test pattern is more concerning for liver scarring and should be interpreted with your medical history, liver enzymes, platelet count trends, imaging, and sometimes other fibrosis tests. A low APRI score is reassuring, especially when other results are stable, but it does not rule out every liver problem. APRI is useful because it is fast, inexpensive, and easy to repeat, but it has important limits.
- APRI uses this formula:
(AST ÷ AST upper limit of normal) ÷ platelet count × 100, with platelet count entered as 10⁹/L. - A low APRI score often suggests a lower chance of advanced liver fibrosis, but it cannot fully exclude liver disease.
- APRI above about 1.0 raises concern for significant fibrosis; APRI above about 2.0 is more concerning for cirrhosis in many hepatitis C studies.
- High AST, low platelets, or both can raise APRI, even when the cause is not liver fibrosis.
- APRI is usually interpreted with ALT, AST, bilirubin, albumin, INR, platelet trends, ultrasound, FibroScan, FIB-4, or specialist evaluation.
- Seek prompt medical care for jaundice, vomiting blood, black stools, confusion, severe abdominal swelling, or easy bleeding.
Table of Contents
- What the APRI Score Measures
- APRI Score Formula and Calculator
- APRI Score Results and Cutoffs
- Why AST and Platelets Change the Score
- APRI Score in Liver Disease
- APRI vs FIB-4 and Other Fibrosis Tests
- What to Do After an Abnormal APRI Score
- Common Mistakes When Reading APRI
What the APRI Score Measures
The APRI score estimates the likelihood of liver fibrosis by combining a liver enzyme result, AST, with a platelet count. APRI stands for AST-to-Platelet Ratio Index. AST is short for aspartate aminotransferase, an enzyme found in liver cells, muscle, heart, and other tissues. Platelets are blood cells that help with clotting and are commonly measured as part of a complete blood count.
Fibrosis means scar tissue has formed in the liver. When liver injury continues for months or years, the liver repairs itself by laying down collagen and other scar-like material. Mild fibrosis may not cause symptoms. Advanced fibrosis can distort the liver’s structure and increase the risk of portal hypertension, fluid buildup, varices, liver failure, and liver cancer. Cirrhosis is the most advanced stage of scarring.
APRI does not measure scar tissue directly. Instead, it uses a pattern that often appears as liver scarring becomes more advanced: AST tends to rise, and platelets tend to fall. The score turns that pattern into a number.
APRI is called a noninvasive fibrosis score because it uses routine blood tests rather than a liver biopsy. It can help decide who may need closer evaluation, but it is not a stand-alone diagnosis. A person with a high APRI may need elastography, liver ultrasound, viral hepatitis testing, iron studies, autoimmune liver testing, or referral to a liver specialist. A person with a low APRI may still need follow-up if liver enzymes remain abnormal or risk factors are strong.
APRI is most useful when the clinical question is about liver fibrosis risk. It is less useful for short-term liver enzyme spikes from a new medication, recent intense exercise, acute viral illness, alcohol binge, muscle injury, or sudden bile duct blockage. In those cases, AST may rise for reasons that do not reflect long-term liver scarring.
APRI Score Formula and Calculator
The APRI score uses AST, the lab’s AST upper limit of normal, and platelet count. The formula is:
APRI = [(AST ÷ AST upper limit of normal) ÷ platelet count] × 100
The platelet count must be entered as 10⁹/L. Many lab reports already show platelets this way. For example, a platelet count of 180 × 10⁹/L may also appear as 180 K/µL or 180,000/µL, depending on the lab format. In APRI, that value should be entered as 180.
Example APRI calculation
Suppose a person has:
- AST: 80 U/L
- AST upper limit of normal: 40 U/L
- Platelet count: 160 × 10⁹/L
First divide AST by the AST upper limit of normal:
80 ÷ 40 = 2
Then divide by the platelet count:
2 ÷ 160 = 0.0125
Then multiply by 100:
0.0125 × 100 = 1.25
The APRI score is 1.25. In many chronic hepatitis C studies, that would raise concern for significant fibrosis, but it would not prove cirrhosis.
APRI calculator table
| AST | AST upper limit of normal | Platelet count | Approximate APRI |
|---|---|---|---|
| 40 U/L | 40 U/L | 250 × 10⁹/L | 0.40 |
| 80 U/L | 40 U/L | 200 × 10⁹/L | 1.00 |
| 80 U/L | 40 U/L | 100 × 10⁹/L | 2.00 |
| 120 U/L | 40 U/L | 100 × 10⁹/L | 3.00 |
The table shows why platelet count has a large effect. Two people can have the same AST result but very different APRI scores if one has a much lower platelet count.
The AST upper limit of normal matters too. Some calculators use a fixed value such as 40 U/L. Others ask for the upper limit printed on your lab report. Using the lab’s own upper limit is usually more accurate because reference ranges vary by laboratory method, sex, and local reporting standards. If your AST report shows a different upper limit, use the value from that report.
APRI should be calculated from blood tests drawn around the same time. Using AST from one month and platelets from another month can mislead, especially if the platelet count is changing or the liver enzyme elevation is temporary.
APRI Score Results and Cutoffs
APRI results are usually interpreted with cutoffs rather than one universal “normal range.” The original and commonly used cutoffs came mainly from chronic hepatitis C research, so they do not perform equally well in every liver condition.
A very low APRI score makes advanced fibrosis less likely. A high APRI score makes significant fibrosis or cirrhosis more likely. Scores in the middle are common and often need another test.
| APRI score | Common interpretation | Usual next step |
|---|---|---|
| Below 0.5 | Lower likelihood of significant fibrosis in many settings | Review the whole liver panel and risk factors; repeat if liver tests stay abnormal |
| 0.5 to 1.0 | Indeterminate or mild concern depending on context | Compare with prior results and consider FIB-4 or elastography |
| Above 1.0 | Higher concern for significant fibrosis, especially in chronic viral hepatitis | Further fibrosis assessment is commonly appropriate |
| Above 2.0 | More concerning for cirrhosis in many hepatitis C studies | Prompt clinical review, imaging, and cirrhosis-related evaluation may be needed |
These cutoffs are not absolute. A score of 0.4 does not guarantee a healthy liver. A score of 2.1 does not automatically mean cirrhosis. The score changes with AST and platelets, and both can be affected by conditions outside chronic liver scarring.
APRI is often better at identifying people at the extremes than at separating mild, moderate, and advanced fibrosis in the middle range. For example, a person with APRI 0.25, normal albumin, normal INR, normal bilirubin, normal platelets, and no ongoing liver risk factors is usually less concerning than a person with APRI 1.4, low platelets, enlarged spleen, high bilirubin, and long-standing hepatitis C.
Trends also matter. A stable APRI around 0.4 over several years is different from a rise from 0.4 to 1.3 over 12 months. A falling platelet count can be especially important because platelets may decline as portal pressure rises, the spleen enlarges, or bone marrow function changes. A single abnormal score should be repeated or confirmed unless the clinical picture already points to advanced liver disease.
Why AST and Platelets Change the Score
APRI rises when AST is high, platelet count is low, or both. Understanding those two inputs helps prevent overreaction and underreaction.
Why AST may be high
AST can rise when liver cells are irritated, inflamed, injured, or dying. Common liver-related causes include hepatitis B, hepatitis C, fatty liver disease, alcohol-related liver injury, medication-related liver injury, autoimmune hepatitis, hemochromatosis, Wilson disease, and bile duct disease.
AST is not liver-specific. It can also rise after intense exercise, muscle injury, seizures, heart injury, hemolysis, and some systemic illnesses. This is why APRI can look worse after a muscle-related AST rise even if liver scarring has not changed. When muscle injury is possible, doctors may check creatine kinase and compare AST with ALT. A broader pattern such as CK, AST, and LDH can help separate muscle injury from liver injury.
AST is usually interpreted alongside ALT. ALT is more liver-focused than AST, although it is not perfect either. In many liver conditions, ALT and AST rise together. In some alcohol-related patterns, AST may be higher than ALT. A separate ALT and AST pattern can add context before assuming an APRI result reflects fibrosis.
Why platelets may be low
Platelets may fall in advanced liver disease for several reasons. Portal hypertension can enlarge the spleen, causing it to hold onto more platelets. Reduced liver production of thrombopoietin, a hormone involved in platelet production, may also contribute. Chronic inflammation, alcohol use, viral infections, medications, immune platelet destruction, bone marrow disease, and nutritional deficiencies can lower platelets too.
Because platelets have many possible causes, a low platelet count should not be blamed on cirrhosis without evidence. A person with immune thrombocytopenia, chemotherapy exposure, certain infections, or inherited low platelets may have a high APRI even without advanced liver fibrosis. The same caution applies to platelet clumping, which can falsely lower the reported platelet count unless the lab identifies the issue.
A low platelet count becomes more concerning for liver disease when it appears with other findings such as high AST, high bilirubin, low albumin, prolonged INR, enlarged spleen, abnormal liver imaging, or known chronic hepatitis.
APRI Score in Liver Disease
APRI was originally developed in chronic hepatitis C, and that remains one of the settings where its cutoffs are best known. It has also been studied in hepatitis B, alcohol-related liver disease, and fatty liver disease, but performance varies.
Chronic hepatitis C
In chronic hepatitis C, APRI can help estimate the chance of significant fibrosis or cirrhosis. Historically, it was useful because hepatitis C often required decisions about treatment urgency, biopsy, and specialist referral. Today, direct-acting antiviral treatment can cure most hepatitis C infections, but fibrosis staging still matters. People with advanced fibrosis or cirrhosis need ongoing monitoring even after viral cure, including care for portal hypertension and liver cancer risk.
A high APRI in someone with hepatitis C should prompt fibrosis assessment rather than delay care. A low APRI is reassuring, but it does not remove the need to treat hepatitis C or evaluate other abnormal liver findings.
Chronic hepatitis B
In hepatitis B, APRI can help in settings where elastography or biopsy is not available, but it is less precise than a full clinical assessment. Hepatitis B can flare, quiet down, and flare again. During a flare, AST may rise sharply and temporarily increase APRI. Treatment decisions for hepatitis B often depend on HBV DNA level, ALT, age, fibrosis stage, family history, pregnancy status, coinfections, and cirrhosis status.
A person with hepatitis B and high APRI needs careful interpretation. The score may reflect advanced fibrosis, an active inflammatory flare, or both. Doctors often combine APRI with viral load, ALT, ultrasound, elastography, and sometimes other markers.
Fatty liver disease and metabolic risk
In metabolic dysfunction-associated steatotic liver disease, formerly often called NAFLD, APRI is not usually the preferred first score. FIB-4 is more commonly used in primary care pathways because it includes age, AST, ALT, and platelets. Still, APRI may appear in lab portals, calculators, studies, or global health settings.
Fatty liver disease can exist with normal AST and ALT, so a low APRI does not rule it out. Many people with fatty liver have metabolic risk markers such as high triglycerides, insulin resistance, type 2 diabetes, central weight gain, or high blood pressure. A metabolic syndrome blood test panel can help frame the risk pattern, but fibrosis risk still requires liver-focused assessment.
Alcohol-related liver disease
APRI may rise in alcohol-related liver injury because AST can increase and platelets can fall. Alcohol can affect the liver, bone marrow, nutrition, spleen size, and clotting system. In alcohol-related patterns, AST is often higher than ALT, and GGT may also be elevated. The AST/ALT ratio and GGT pattern can provide useful context.
A high APRI in someone who drinks heavily should be taken seriously, but it still needs confirmation. Recent alcohol-related inflammation can raise AST quickly, while platelets may improve after abstinence if bone marrow suppression or alcohol-related effects are contributing.
APRI vs FIB-4 and Other Fibrosis Tests
APRI is one of several noninvasive ways to estimate liver fibrosis. Each test has strengths and limits. No blood score is perfect.
| Test or score | What it uses | Strength | Main limitation |
|---|---|---|---|
| APRI | AST, AST upper limit of normal, platelets | Simple, inexpensive, available from routine labs | Less accurate in many non-hepatitis C settings and often indeterminate |
| FIB-4 | Age, AST, ALT, platelets | Widely used for fatty liver risk pathways and primary care triage | Age can strongly affect the score, especially in older adults |
| Transient elastography | Liver stiffness measurement | More direct estimate of stiffness and fibrosis risk | Can be affected by inflammation, congestion, cholestasis, and technical factors |
| Enhanced Liver Fibrosis test | Serum fibrosis markers | Useful in some fatty liver pathways | Availability and cutoffs vary by health system |
| Liver biopsy | Microscopic liver tissue sample | Can assess fibrosis, inflammation, fat, and other diagnoses | Invasive, small sampling area, bleeding risk, not needed for everyone |
FIB-4 is often preferred when evaluating fatty liver disease because it has been built into many clinical pathways. APRI remains useful because it is simple and has a long history, especially in chronic viral hepatitis and settings where more advanced tests are not accessible. A dedicated comparison of FIB-4 and APRI can be helpful when the two scores disagree.
Discordant results are common. For example, APRI may be high because AST is temporarily elevated after muscle injury, while FIB-4 may also rise because it includes AST. Elastography may be normal, suggesting the blood score was a false alarm. The reverse can also happen: a person may have normal AST but significant fibrosis on elastography. That can occur because liver enzymes do not always track scarring.
Doctors often use a stepwise approach. A simple blood score identifies people at low or higher risk. People in the higher or uncertain range then get elastography or a specialist review. This reduces unnecessary biopsy while still finding people who need closer care.
What to Do After an Abnormal APRI Score
An abnormal APRI score should lead to context, confirmation, and follow-up rather than panic. The right next step depends on how high the score is, whether it is new, and what else is abnormal.
Start by checking the inputs. Confirm that AST and platelets were taken from the same blood draw or same time period. Make sure the platelet count was entered in the correct unit. Confirm that the AST upper limit of normal came from the lab report or from the calculator’s stated assumption.
Next, review the rest of the liver panel. ALT, alkaline phosphatase, GGT, bilirubin, albumin, and total protein can show whether the pattern looks like liver cell injury, bile duct obstruction, inflammation, or reduced liver synthetic function. A liver function tests panel gives more context than AST alone.
Then look for signs of reduced liver function or portal hypertension. Low albumin, prolonged INR, low platelets, high bilirubin, enlarged spleen, abdominal fluid, varices, and nodular liver contour on imaging are more concerning than a mild isolated APRI rise.
Common follow-up steps may include:
- Repeating AST, ALT, and platelet count after a short interval if a temporary cause is possible
- Checking hepatitis B and hepatitis C status if not already known
- Reviewing alcohol intake, medications, supplements, and acetaminophen exposure
- Ordering iron studies, ferritin, autoimmune liver tests, or metabolic tests when the pattern fits
- Getting liver ultrasound to look for fatty liver, cirrhosis features, bile duct dilation, spleen enlargement, or masses
- Using transient elastography, such as FibroScan, to estimate liver stiffness
- Referring to hepatology or gastroenterology when APRI is high, platelets are low, or other liver function markers are abnormal
Certain symptoms need urgent medical evaluation because they may suggest decompensated liver disease or serious bleeding. These include vomiting blood, black tarry stools, confusion, severe sleepiness, new jaundice, rapidly increasing abdominal swelling, fever with abdominal pain, fainting, or bleeding that is hard to stop.
If APRI is high because platelets are very low, bleeding risk should be considered separately. Platelets are part of clot formation, but bleeding risk in liver disease is complex and also involves INR, fibrinogen, blood vessel pressure, kidney function, medications, and active bleeding symptoms. A platelet count and platelet function discussion may be needed if bruising, nosebleeds, heavy menstrual bleeding, or procedures are involved.
Common Mistakes When Reading APRI
One common mistake is treating APRI as a yes-or-no cirrhosis test. It is not. APRI estimates probability. A high result supports further evaluation; it does not replace imaging, elastography, clinical examination, or specialist interpretation.
Another mistake is using the wrong platelet unit. Platelets must be entered as 10⁹/L. If a lab report shows 180,000/µL, enter 180, not 180,000. Entering the wrong unit can create a wildly incorrect score.
A third mistake is ignoring temporary AST elevations. AST can rise after hard exercise, muscle injury, alcohol use, medication reactions, acute viral illness, or hemolysis. Repeating the test after the temporary trigger has resolved may produce a very different APRI.
A fourth mistake is assuming normal liver enzymes rule out fibrosis. Some people with advanced fibrosis have only mild liver enzyme elevations or even normal AST and ALT at times. This is especially important in fatty liver disease, older adults, diabetes, and long-standing viral hepatitis.
A fifth mistake is overlooking the platelet trend. A platelet count that has dropped from 240 to 135 × 10⁹/L over several years may matter even if it is still close to the lab’s lower limit. Trends can reveal a developing pattern before a single result looks dramatic.
A sixth mistake is applying hepatitis C cutoffs to every condition with equal confidence. APRI performs differently across hepatitis C, hepatitis B, fatty liver disease, alcohol-related liver disease, and mixed causes. The score is a starting point, not the final answer.
APRI is most helpful when it is treated as one piece of a liver fibrosis risk picture. It can flag a pattern that deserves attention, especially when AST is persistently high or platelets are falling. It can also reassure when the score is low and the rest of the clinical picture is stable. The safest interpretation comes from combining the number with symptoms, risk factors, trends, and other liver tests.
References
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update 2021 (Guideline)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease 2023 (Guideline)
- Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection 2024 (Guideline)
- Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection 2018 (Guideline)
- A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C 2003 (Original Study)
Disclaimer
APRI is a screening and risk-stratification score, not a diagnosis. Liver fibrosis, cirrhosis, low platelets, and abnormal AST can have many causes, so results should be reviewed with a qualified clinician who can interpret the full medical picture. Seek urgent care for signs of severe liver disease or bleeding, including confusion, vomiting blood, black stools, severe jaundice, or rapidly worsening abdominal swelling.
